Invest in intelligence that delivers

US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson’s Disease Treatments

US Neurologists express enthusiasm for new ways to administer current treatments and future disease modifying therapies, according to Spherix Global Insights.  EXTON, PA., May 9, 2024 – Even as the incidence of Parkinson’s disease (PD) continues to increase with 90,000 new diagnoses each year1 in the US, the treatment landscape has remained relatively stagnant. Yet, neurologists […]

Leqembi launch hamstrung by physicians’ ‘therapeutic nihilism’

Eisai has recently outlined a range of ways to kick-start Leqembi’s lackluster launch, from increasing the number of neurology account specialists to adding a subcutaneous option. But a Reuters report suggests the company faces a more fundamental problem: Physicians still see Alzheimer’s disease as untreatable. The Japanese drugmaker said 2,000 patients in the U.S. were receiving the amyloid-busting antibody […]

How Do Companies Avert Further Frustration Among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Failure and Donanemab’s (Lilly) FDA delay?

Spherix Global Insights captures neurologists’ reactions within 48 hours of these pivotal announcements. EXTON, PA., March 12, 2024 — For neurologists tasked with delivering the distressing diagnosis of Amyotrophic Lateral Sclerosis (ALS) or Alzheimer’s Disease (AD), the upcoming months may prove equally heart-wrenching. They face the daunting responsibility of informing patients and caregivers that not […]

Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen’s Leqembi, According to Spherix Global Insights Neurologist Survey

Adoption of Leqembi is even slower than expected.  EXTON, PA., February 22, 2024 — The 2023 announcement of newly approved disease-modifying therapy (DMT) Leqembi (lecanemab) for Alzheimer’s Disease (AD) sparked eager anticipation within both the medical community and among families nationwide. The debut of Aduhelm from Biogen in 2021 brought with it a wave of […]

Parkinson’s Disease Patient Identification and Education Will Need to Improve When New Disease Modifying Therapies Are Approved, According to Spherix Global Insights

Earlier screening will be needed in the age of biomarkers.  EXTON, PA., February 16, 2024 — Millions of people worldwide are affected by Parkinson’s disease (PD), prompting the need for effective disease-modifying therapies (DMTs) to target this degenerative condition. With gene therapies emerging as an exciting potential mechanism of action (MOA) for future treatment, their […]

Potential for new Huntington’s treatment sparks optimism for MDs

But US neurologists also express frustration with current lack of therapies Neurologists in the U.S. are optimistic about the potential for a new treatment for Huntington’s disease, but emphasize the need for therapies that halt nerve degeneration before symptom onset, according to a report by Spherix Global Insights. Most of the specialist physicians surveyed hoped for a […]

US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Halting Neurodegeneration as Leading Treatment Priority

According to Spherix Global Insights’ first market landscape study on Huntington’s disease, neurologists are staking their hopes on gene therapy. EXTON, Pa., January 3, 2024 – Huntington’s disease (HD) could be called the perfect storm of neurodegenerative diseases. It causes a loss of critical striatal neurons which affect not only motor function – causing symptoms […]

US neurologists favorably view BTK inhibitors as potential MS therapies

But Spherix surveys across 2023 may not reflect recent setbacks in clinical trials More than one-third of neurologists in the U.S. believe Bruton’s tyrosine kinase (BTK) inhibitors could be of pivotal significance as a future treatment of multiple sclerosis (MS), according to findings of a recent Spherix Global Insights’ survey. “Through Spherix’s quarterly RealTime Dynamix market tracker, neurologists and […]

U.S. Neurologists Eagerly Await Promising Oral Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis Treatment Pipeline, Though Recent Trial Readouts Might Hamper Initial Excitement

Efficacy and safety of pipeline multiple sclerosis assets viewed as increasingly important characteristics, according to Spherix Global Insights.  [Exton PA, December 13, 2023] — Several clinical trials are underway for Bruton’s tyrosine kinase inhibitors (BTKi) targeting relapsing and progressive multiple sclerosis (RMS/PPMS). These BTKis, administered orally, possess the advantage of easy dosing while leveraging their […]

Survey finds neurologists seek to minimize side effects of treatment in Parkinson’s

Fewer than half of those dealing with Parkinson’s disease in the United States are able to gain clinical control of symptoms without experiencing side effects, according to results of a new study. Spherix Global engaged its initial Insights’ Market Dynamix to canvas more than 100 neurologists, employing a combination of quantitative survey and qualitative interview […]

Sign up for alerts, market insights and exclusive content in your inbox.

Spherix is excited to announce our expansion into an additional, rapidly evolving specialty market:


Throughout 2024, we will be publishing over
10 groundbreaking studies covering a wide range of indications within classical hematology.